Assessing anti-malarial drug effects ex vivo using the haemozoin detection assay

Maria Rebelo¹,²*, Carolina Tempera¹, José F Fernandes²,³,⁴, Martin P Grobusch²,³,⁴ and Thomas Hänscheid¹,²,⁵

Abstract

Background: In vitro sensitivity assays are crucial to detect and monitor drug resistance. Plasmodium falciparum has developed resistance to almost all anti-malarial drugs. Although different in vitro drug assays are available, some of their inherent characteristics limit their application, especially in the field. A recently developed approach based on the flow cytometric detection of haemozoin (Hz) allowed reagent-free monitoring of parasite maturation and detection of drug effects in culture-adapted parasites. In this study, the set-up, performance and usefulness of this novel assay were investigated under field conditions in Gabon.

Methods: An existing flow cytometer (Cyflow Blue) was modified on site to detect light depolarization caused by Hz. Blood from malaria patients was incubated for 72 hrs with increasing concentrations of chloroquine, artesunate and artemisinin. The percentage of depolarizing red blood cells (RBC) was used as maturation indicator and measured at 24, 48 and 72 hrs of incubation to determine parasite growth and drug effects.

Results: The flow cytometer was easily adapted on site to detect light depolarization caused by Hz. Analysis of ex vivo cultures of parasites, obtained from blood samples of malaria patients, showed four different growth profiles. In 39/46 samples, 50% inhibitory concentrations (IC50) were successfully determined. IC50 values for chloroquine were higher than 200 nM in 70% of the samples, indicating the presence of chloroquine-resistant parasites. For artesunate and artemisinin, IC50 values ranged from 0.9 to 60 nM and from 2.2 nM to 124 nM, respectively, indicating fully sensitive parasites.

Conclusion: Flow cytometric detection of Hz allowed the detection of drug effects in blood samples from malaria patients, without using additional reagents or complex protocols. Adjustment of the initial parasitaemia was not required, which greatly simplifies the protocol, although it may lead to different IC50 values. Further investigation of set-up conditions of the Hz assay, as well as future studies in various settings should be performed to further determine the usefulness of this assay as a tool for rapid resistance testing in malaria-endemic countries.

Keywords: Malaria, field trial, Anti-malarial sensitivity testing, Resistance, Flow cytometry, Haemozoin

Background

In the last decade, the number of malaria deaths has decreased in large part due to the availability of effective treatments, in particular artemisinin combination therapy (ACT) [1]. However, these achievements are in danger and might even be reversed because parasites with prolonged parasite clearance times (PCT), observed in patients treated with ACT, have emerged in Southeast Asia [2,3]. Indeed, this is considered an early sign of the development of parasite resistance [2,3] and a major concern in the fight against malaria, as illustrated by the WHO Global Plan for Artemisinin Resistance Containment issued in 2011 [4]. Artemisinin resistance, currently defined as prolonged PCT, has spread across Southeast Asia [5]. Recently, a Vietnamese patient who apparently acquired malaria in Angola failed to respond to intravenous artesunate/clindamycin and an oral ACT after returning to Vietnam [6]. It is not unlikely that it will emerge in sub-Saharan Africa, and drug sensitivities should be monitored pro-actively. In this scenario, in vitro sensitivity assays may play a crucial role in the
future. In vitro assays allow reducing host-related factors and thus, provide an objective insight into the intrinsic sensitivity of malaria parasites.

Several phenotypic and genotypic methods have been developed and tried for drug testing in the field [7]. Genetic resistance markers are known for some anti-malarial drugs, but are not yet able to predict sensitivity to all commonly used anti-malarial drugs [8]. Only recently, alterations in the kelch13 gene were linked to delayed parasite clearance in artemisinin-treated patients [9]. Thus, phenotypic assays continue to be important for detection of resistance and validation of genetic markers. The main phenotypic assays successfully used to detect drug resistance in the field include: (i) the microscopic schizont maturation test [10]; (ii) the incorporation of radioactive hypoxanthine [11]; (iii) ELISA assays for detection of pLDH [12] and HRP2 [13] antigens; and, (iv) fluorescent-based techniques using either fluorometry [14] or flow cytometry [15] to detect parasite DNA/RNA. However, inherent limitations are common, especially during field applications. The supply, handling and disposal of radioactive isotopes are major obstacles. Microscopy is labour-intensive and subjective, although it has a rather quick turn-around time (24–30 hrs) when compared to other techniques, especially ELISA-based methods, which can take up to 72 or even 96 hrs [16,17]. Moreover, assays may require the use of, often, expensive antibodies or DNA/RNA stains, highlighting the issues of adequate storage and cold chain as well as limited shelf life.

Regarding flow cytometry, the majority of cytometric methods apply combinations of dyes to reliably detect infected red blood cells (iRBC), which implies a complex multiparameter analysis [15,18]. Ideally, if parasite maturation was detectable using a direct and simple measurement of a product from the parasite, the need for additional reagents would be avoided.

Haemozoin (Hz) is produced in increasing amounts by the parasite as it matures inside the iRBC, constituting an optimal maturation indicator [10]. Measuring Hz with a simple flow cytometry method allows detection of parasite maturation and drug effects as early as 18 hrs after incubation in culture-adapted laboratory strains [19].

The objectives of this study were to evaluate if the Hz detection assay could be easily set up in a remote malaria-endemic area, and to assess whether anti-malarial drug effects could be detected in wild-type strains obtained from malaria patients, using a simple protocol.

Methods
The study was carried out at the Centre de Recherches Médicales de Lambaréné (CERMEL) in Gabon, a malaria-endemic region in Africa. Ethical approval was obtained from the Institutional Review Board of the Medical Research Unit (CERMEL) of the International Foundation of the Albert Schweitzer Hospital.

Samples
EDTA anti-coagulated blood samples from malaria patients were obtained from the Clinical Analysis Laboratory of the Albert Schweitzer Hospital after the samples had been processed for full blood count (FBC). Malaria diagnosis and parasite loads (number of parasites/μl of blood) were determined by standard microscopic observation of Giemsa-stained thick blood films. Briefly, parasitaemia was quantified by counting the number of parasites per microscopic field from a defined volume of blood (10 μl) spread on a defined area (1.8 cm²), as described elsewhere [20]. RBCs from these blood samples were washed twice in culture medium before further use.

Flow cytometric detection of depolarized side-scattered light
Flow cytometric analysis was performed using a CyFlow Blue (Partec, Münster, Germany) available on site. The existing configuration, which was modified on site for this study and is shown in Figure 1, consisted of forward scatter (FSC), side scatter (SSC) and three fluorescent detectors (FL1, FL2 and FL3). A set of four optical filters was necessary, as shown in Figure 1B: (1) a 500-nm dichroic mirror; (2) a 50:50 beam-splitter; (3) a 488-nm vertical polarizer; and, (4) a 488-nm horizontal polarizer. Briefly, a 500-nm dichroic mirror (DM) (B1) was placed on the site of the original 540-nm DM and the other original 500-nm DM was replaced by a 50:50 beam-splitter (B2), which allowed the creation of two SSC detectors (Figure 1). A 488-nm filter coupled with a polarizer in the same orientation as the incident laser beam (vertical) was placed in front of one of the SSC detectors. Another 488-nm filter coupled with a polarizer perpendicularly orientated in relation to the laser beam (horizontal) was placed in front of the other SSC detector, allowing the detection of light depolarization (Figure 1C). The optical components required to modify the optical bench of flow cytometers can be obtained directly from the instruments’ manufacturer.

Anti-malarial drugs
Samples were tested against different concentrations of chloroquine, artemunate and artemisinin (Sigma Aldrich, St Louis, MO, USA). Stock solutions of chloroquine were prepared in sterile water, and artemisinin and artemunate were prepared in pure methanol. Doubling concentrations, ranging from 25 to 200 nM for chloroquine and from 0.12 to 128 nM for artemisinin and artemunate, were prepared from the stock solutions in complete malaria culture medium (CMCM), which consists of RPMI 1640 supplemented with 25 mM HEPES,
2.4 mM L-glutamine, 50 μg/mL gentamicin, 0.5% w/v Albumax, 11 mM glucose, 1.47 mM hypoxanthine and 37.3 mM NaHCO3.

Each drug concentration was tested in triplicate.

Haemozoin detection assay

RBCs obtained from malaria patients were diluted at a haematocrit of 5% in CMCM. To simplify the assay, parasitaemia was not adjusted so that, eventually, the use of uninfected blood could be avoided. A volume of 100 μL was distributed into the wells of a 96-well plate, previously loaded with 100 μL of anti-malarial drugs at different concentrations, or 100 μL of CMCM for the drug-free controls, respectively. Plates were incubated for 72 hrs at 37°C in 5% CO2 atmosphere. Flow cytometric measurements were performed at 24, 48 and 72 hrs of incubation. Parasite maturation from ring-stage to schizonts was assessed based on the increase in the percentage of Hz-containing cells overtime, as described before [19]. To assess parasite replication (re-invasion), the same samples were stained with SYBR green I at 1x (Invitrogen, Carlsbad, CA, USA), as described elsewhere [19].

Histidine-rich protein-2 (HRP2) enzyme-linked immunosorbent assay (ELISA)

For the HRP2-ELISA, RBCs were diluted in CMCM at a haematocrit of 3%. Parasitaemia was adjusted to 0.05% using RBCs obtained from healthy volunteer donors. A volume of 100 μL was distributed into the wells of a 96-well plate, previously loaded with 100 μL of anti-malarial drugs at different concentrations or 100 μL of CMCM for the drug-free controls. Plates were incubated for
72 hrs at 37°C in 5% CO₂, after which they were frozen at −20°C until the HRP2-ELISA was performed according to standard procedures [21].

Data analysis
Flow cytometry results were analysed using FlowJo software (version 9.0.2, Tree Star Inc., Oregon, USA). Depolarizing events were defined in plots of SSC versus depolarized-SSC, as those with a signal above the background observed in the uninfected control (gate in Figure 2A and B). To determine SYBR green I-positive cells, green fluorescence (FL1) versus red fluorescence (FL3) plots were used. The FL1 detector had a 527/30 band-pass filter and FL2 had a 620-nm long-pass filter. SYBR green I-positive events were established based on a stained uninfected control and had to be adjusted at each time point, always using the uninfected SYBR green I-stained sample from the corresponding time point. A non-linear regression model (sigmoidal dose–response/variable slope) was used to calculate the individual 50% inhibitory concentrations, with SigmaPlot-Systat Software (Chicago, IL, USA). Only those samples with a ≥2 ratio of drug-free control to highest drug concentration were included.

Results and discussion
Growth and maturation of wild-type Plasmodium falciparum strains
Forty-six samples from malaria patients were analysed during this study. Parasite loads ranged from 50 to 452,000 parasites/μL of blood (median of 15,000 parasites/μL). Ex vivo cultures of infected RBCs showed that parasites had four different growth profiles (Table): (i) seven samples showed no maturation, as defined by an increase in depolarization; (ii) another eight samples
showed maturation at 24 hrs and replication at 48 hrs; (iii) 17 samples showed maturation at 24 hrs but no reinvasion occurred; and, (iv) 14 samples had a delay in parasite growth, with maturation being observed at 48 hrs and replication at 72 hrs.

One crucial step in the in vitro sensitivity assays is the culture of parasites [22]. Maturation of *Plasmodium falciparum* from early rings to late schizonts takes 42–48 hrs *in vitro* [23] and consequently, an increase in parasitaemia can only be observed every 42–48 hrs, after re-invasion of RBCs occurs. Differences in ex vivo parasite maturation and replication have already been observed in strains obtained directly from different patients [24,25]. Indeed many factors related to the protocol, the host and the parasite itself might greatly influence the in vitro growth of parasites.

Regarding the protocol factors, such as the type of anticoagulant used to collect the blood from the patients to the atmosphere where the parasites will be incubated, have to be taken into account [7]. During this study EDTA-collected blood was used. Although the use of EDTA is discouraged by the reference protocol from MR4 [26] it has been shown by different studies that EDTA-collected blood can be successfully used for ex vivo drug testing [27–31]. In one of these reports even long-term cultures of parasites present in patients’ blood were accomplished [31]. Moreover, the use of specific anticoagulants requires drawing more blood just for the purpose of sensitivity testing. This can be avoided by using EDTA-anticoagulated blood, which was obtained as part of the routine FBC analysis, preventing all inherent problems associated with an extra blood drawing.

The incubation atmosphere recommended for *P. falciparum* growth in culture include the use of a low O2 atmosphere [26]. However, such mixed gas atmospheres may not be available in the resource-limited settings found in malaria endemic countries. Because of this, it has been investigated whether a simple 5% CO2 atmosphere could be used instead without compromising parasite survival after drug treatment [32]. Results showed no differences in parasite survival between trilgas (5% CO2, 5% O2, 90% N2), candle jar or a 5% CO2 atmosphere [32].

Undoubtedly, host-specific factors, often difficult to control, ranging from the immune response to the presence of pharmacologically active substances might influence the growth of the parasite in vitro. Indeed, the fact that some of the patients might already have been treated at the time of blood collection during this study cannot be discarded, possibly explaining some of the differences observed in the parasites’ growth profiles. Yet, it is very difficult to control for all these factors and this might not only imply detailed histories, but eventually laboratory test to confirm immune status or presence of drug-metabolites. Perhaps explaining why very few studies on this file are including such detailed information.

Conversely, parasite-related factors may even be more important. The delay between sample collection and processing influences the viability of freshly collected clinical isolates, because it is considerably decreased after a sample has been kept for several hours at room temperature [7]. However, in one study where all 43 samples were cultured within 30 minutes of collection [25], 50% developed into schizonts within 27 hrs, while the other half reached schizont stage only between 28 and 63 hrs. In this study no correlation between the delay until culture and any of the four parasite growth patterns was observed, supporting the idea that possible host factors may have been more relevant.

**Detection of anti-malarial drug effects by the haemozoin assay**

In *P. falciparum*-infected patients the majority of circulating iRBC are ring forms that contain little or no detectable Hz, as observed in a previous report whereby flow cytometric assessment of Hz these forms could not be detected [33]. This study confirms this observation, as at 0 hrs, no difference in depolarizing events was observed between the infected and the uninfected samples (Figure 2A and B). Only after incubation the percentage of depolarizing cells increased, indicating higher Hz content and, thus maturation (Figure 2B), seen in drug-free controls or drug-resistant parasites. This contrasts with diminished or absent depolarizing events when antimalarial drugs are effective (Figure 2C). Drug inhibitory effects were determined in 39/46 (85%) of samples, in which parasite maturation was observed (groups 2, 3 and 4). In 25 samples (groups 2 and 3), drug effects were measurable at 24 hrs, as expected from culture-adapted strains [19]. In the remaining 14 samples (group 4) parasite maturation was delayed; however, it was still possible to detect drug effects at 48 hrs of incubation.

**IC50 values of chloroquine and artemisinins**

The IC50 values are shown in the Table 1. There was a poor correlation between the IC50 values of individual samples and the different assays. In fact, this is commonly observed even when using the same laboratory-adapted strain [19]. Indeed, several factors, such as the initial parasitaemia, the haematocrit and the end point for measuring parasite growth can influence IC50 values [7,34]. Samples with higher initial parasitaemia (group 3), showed increased IC50 values for artesunate and artemisinin (Table). Apparently, a higher initial parasitaemia may be associated with an increase in inhibitory drug concentration of artemisinin, artesunate, chloroquine, and mefloquine [11], which could explain some of the increase observed in the IC50 values. Interestingly, mean IC50 values for artesunate and artemisinin in isolates that had a delayed growth (group 4) were somewhat
lower than in groups 2 and 3, where maturation was
detected at 24 hrs. This could be due to the different growth
profile of drug exposed and non-exposed parasites in
group 4. Overall, IC50 values ranged from 0.9 to 60 nM
and from 2.2 nM to 124 nM for artesunate and artemisi-
nin, respectively (Figure 3). These values are higher than
previously described in the same region, using the HRP-2
assay [35]. Because several assay-related factors can influ-
ence IC50 values they may not be directly comparable be-
tween different assays [7,34]. In the previous study, the
final haematocrit was 1.5% [35], while in the Hz detection
assay it was 2.5%. It has been observed that higher haema-
tocrits may cause an increase in IC50 values [34]. Prelim-
inary data using the same culture-adapted strain showed
that the IC50 value for dihydroartemisinin increases from
1.7 nM to 7.5 nM when the haematocrit of the sample is
raised from 1 to 2.5% (unpublished data).

For chloroquine, 70% of the samples had IC50 values
higher than 200 nM, indicating resistance, which is in
line with an earlier reports and which is explained
through the high usage of amodiaquine, many years after
the use of chloroquine had been curbed and finally
abandoned [36,37]. In Malawi [38,39], Kenya [40] and
Tanzania [41], chloroquine resistance decreased after its
withdrawal, contrary to the study site, even though
chloroquine treatment was discontinued 11 years ago, as
observed by others [37,42]. One explanation brought
forward is the use of artesunate/amodiaquine, because
amodiaquine appears to select mutant
\( pfcr \) allele, which
is responsible for chloroquine resistance [43].

Interestingly, the Hz-detection assay showed in some
of the chloroquine-resistant strains that the percentage
of Hz-containing cells increased as chloroquine concen-
tration increased as well (Figure 2C). It is known that
several drugs, specially quinoline-type drugs, directly
interact with Hz, as discussed elsewhere [44]. This inter-
action may lead to alterations in the crystals distribution
within the parasite that may affect the depolarized light
signal. Recently it has been shown that parasites con-
taining several small but distributed Hz crystals can have
a higher depolarized signal than a parasite containing a
single large clump of Hz [45]. In this context it is not
unlikely that at higher concentrations of chloroquine
some of the drug may interact with Hz avoiding its co-
alescence. Thus, explaining why at higher concentrations
of this drug the signal seems to be increased. Certainly,
the mechanism of this observation is not known, and
further investigation is required to understand the exact
cause of this phenomenon.

During this study the HRP2-ELISA was performed
alongside. However, drug effects could only be detected
in 17 samples (37%), with IC50 values ranging from 0.6
to 31 nM for artesunate and 0.6 to 94.8 nM for artemisi-
nin (Figure 3). This success rate appears to be at the
lower end of reported studies with 45% [14], while
others had success rates of 75% [46] and 87% [13]. Of
note, these samples were collected on purpose to be
used exclusively in the scope of these studies. Contrary

---

Table 1  Summarized data of isolates exhibiting different ex vivo growth profiles analysed by the haemozoin assay

| Group | Growth profile | Number of samples | Parasitaemia (median; range) | IC50 Artesunate (mean) | IC50 Artemisinin (mean) |
|-------|----------------|-------------------|----------------------------|-----------------------|------------------------|
| 1     | No maturation  | 7                 | 0.01%; 0.3%; 3.5%; 0.3%    | nd 10.5 nM            | nd 46 nM               |
| 2     | Maturation at 24 hrs and replication at 48 hrs | 8               | 0.001-0.1%; 0.2-2.2%; 0.2-12% | 46 nM 15.2 nM         | 47.3 nM 5.6 nM         |
| 3     | Maturation at 24 hrs but no replication | 17              | 3.5%; 0.3%                  | 10.5 nM 15.2 nM       | 47.3 nM 5.6 nM         |
| 4     | Delayed maturation | 14              | 0.3%                        | nd                    | nd                     |

nd – not determined.

Note: Results from chloroquine were not presented in this Table because the majority of the samples (32 out of 46) had IC50 values higher than 200 nM. Chloroquine had an inhibitory effect in only four samples from group 3 (IC50 mean = 76.8 nM). In ten samples, chloroquine activity could not be determined.
to this, here, samples were collected for other purposes, which might have contributed to a lower success rate. Furthermore, samples were preselected based on their parasitaemias of 0.01% or higher [13], while in this study all samples were included. Apparently, re-invasion of uninfected RBCs (replication) is considered the main criterion for the success of the HRP2 assay [21]. However, even when no schizont maturation is observed after 24 hrs of incubation, samples can still be successfully tested by the HRP2 assay [21]. During this study, most results (14 out of 17) were obtained in samples that exhibited delayed-growing parasites (group 4), whereas drug effects were only detected in two samples from groups 1 and 2, and in five samples from group 3.

Indeed, the low detection limit is a major advantage of the HRP2 assay. For instance, the Hz assay failed to determine drug effects in samples from group 1, possibly due to the low parasitaemias present in this group, which were below the previously reported 0.3% detection limit of the Hz assay [19]. On the other hand, when parasitaemias are higher than 0.1% [21], samples have to be diluted with uninfected RBCs from healthy donors, which can be a limiting step. Results from group 3, where the parasitaemia ranged from 0.2 to 12%, indicate that the Hz detection assay does not seem to require adjustment of the parasitaemia to allow the detection of drug effects.

Field applications of flow cytometry

The optical bench of the CyFlow® flow cytometer available on site had a typical configuration common in most small instruments, consisting of one blue-laser (488 nm) and detectors for FSC, SSC and three fluorescences FL1 (green), FL2 (orange) and FL3 (red) (Figure 1A). For the detection of light depolarization the original set-up was easily modified by simply changing the respective filters and mirrors, even taking advantage of the existing filter holders (Figure 1B). The optical bench layout required for the detection of light depolarization is simple (Figure 1C) and therefore, other instruments should also be easily modifiable, unless they use fiber-optic cables for light collection.

Few studies describe the use of flow cytometry for drug testing in the field [15,47], possibly because of the perceived expense and complexity in setting up and running such instruments. Nowadays the number of simple, robust and portable flow cytometers has increased, including instruments such as the Attune™ (Life Technologies, Carlsbad, USA), the Accuri™C6 (BD Biosciences, La Jolla, USA), the Cyflow Cube 6 (Partec, Münster, Germany), among others. It has been shown that theses instruments can be easily modified to detect Hz-caused light depolarization [45] and most of them can be used with an autosampler for higher throughput [48]. Moreover, the initial purchase costs of these instruments have dropped substantially from those practiced before for larger instruments, allowing them to be used and available in the field. Indeed, recent field studies take advantage of this, by using for example the Accuri C6 [15,47]. Even smaller and simpler instruments used for CD4+ T cell counting in HIV-infected patients exist, such as the CyFlow™miniPOC from Partec, which are used in low-resource settings [49]. Although the way was often difficult, cytometry is no longer the very expensive, high-end technology based on bulky instruments. In the future, simple image cytometers might replace flow cytometers, as they seem to perform a broad range of measurements, and eventually parameters such as light depolarization could be detected as well [50,51].

Opening new avenues for anti-malarial drug testing in the field

This study showed that drug effects of clinically relevant anti-malarial drugs as well as resistance to chloroquine could be assessed by simply detecting Hz. This method measures parasite maturation and does not require re-invasion to occur; consequently, results can be obtained earlier than with other currently available methods, except for microscopy. However, microscopy relies on trained observers’ ability to detect morphological changes of iRBC [52], which sometimes can be rare. Flow cytometric measurements can provide more objective, reliable and effective results than microscopy, as it has been previously observed in a different context [53]. Moreover, it allows the assessment of additional parameters, such as DNA and RNA content, which can improve parasite detection [51]. Finally, drug effects could be detected without having to decrease the sample’s parasitaemia. This may greatly simplify the protocol as it avoids the need to obtain blood from healthy donors. Yet, this seems to lead to increased IC50 values. Thus, whether parasitaemia ought to be adjusted or not should be further investigated.

These findings open new avenues for other Hz-detection methods. Interestingly, several Hz detection methods exist [54-58] and they could possibly be used to detect drug effects as early, or even earlier, than the flow cytometric Hz detection.

Conclusion

This study conducted in the field showed flow cytometry could be easily implemented and performed in field conditions. Flow cytometric detection of Hz could be used as an alternative tool to assess drug effects on parasites obtained directly from patients’ blood samples, without the need for additional reagents or complex protocols. However, further optimization of the Hz assay regarding its set-up conditions, for example, changing the haematocrit, may contribute to obtain IC50 values more
comparable to the ones that have been previously reported [13,59].

Future studies should be performed in various settings, to further investigate the Hz assay and its usefulness as a tool for rapid resistance testing in malaria-endemic countries.

Competing interests

The authors have declared that they have no competing interests.

Authors' contributions

TH, MR and MPG conceived the study. All field experiments were performed by MR, TH and MPG coordinated the project. CT performed the ELSIA assays. MPG and YF assisted with obtaining the samples from malaria patients, provided advice on different aspects of the novel assay and its assessment under field conditions. MR and TH wrote the draft manuscript. All authors contributed to the writing, and approved the final manuscript.

Acknowledgements

This work was supported by the Luso-American Foundation (FLAD-LACR grant: B-AV-109-00007). MR acknowledges Fundação para a Ciência e a Tecnologia for doctoral grant (SFRH/BDE/84630/2012) and Fundação Calouste Gulbenkian for the Award CAML/Gulbenkian for Travel AGCT fellowship. The authors acknowledge the Albert Schweitzer Hospital's central clinic laboratory staff who provided the samples from malaria patients, the co-directors of CERMEIL: Dr Akim Adegnika, Dr Bertrand Lell and Dr Maxime Selidji Agnandji and, finally, Dr Marguerite Massinga Loembe, Head of the CERMEIL Research Laboratory.

Author details

1Instituto de Medicina Molecular, Faculdade de Medicina de Lisboa, Av Prof Egas Moniz, Lisbon P-1649-028, Portugal. 2Centre de Recherches Medicales de Lambaréné – CERMEIL, Albert Schweitzer Hospital, Lambaréné, Gabon. 3Institut für Tropenmedizin, Universität Tübingen, Tübingen, Germany. 4Centre of Tropical Medicine and Travel Medicine, Amsterdam Medical Centre, University of Amsterdam, Amsterdam, The Netherlands. 5Instituto de Microbiologia, Faculdade de Medicina, Lisbon, Portugal.

Received: 26 December 2014 Accepted: 17 March 2015

Published online: 01 April 2015

References

1. Kweka EJ, Mazigo HD, Munga S, Magesa SM, Mborea EG. Challenges to malaria control and success stories in Africa. Global Health Perspectives. 2013;1:71–80.
2. Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008;359:2619–20.
3. Dondorp AM, Nosten F, Yi P, Das D, Phyo AP, Tarning J, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2009;361:455–67.
4. WHO. Global plan for artemisinin resistance containment (GPARC). Geneva: World Health Organization; 2011.
5. Ashley EA, Dhorda M, Fairhurst RM, Amaratunga C, Lim P, Suon S, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med. 2014;371:41–23.
6. Van Hong N, Anambua-Ngwa A, Tuan NQ, Cuong Do D, Giang NT, Van Dung N, et al. Severe malaria not responsive to artemisinin derivatives in man returning from Angola to Vietnam. Emerg Infect Dis. 2014;20:1199–202.
7. Basco LK. Field application of in vitro assays for the sensitivity of human malaria parasites to antimalarial drugs. Geneva, Switzerland: WHO Press; 2007.
8. Woodrow CJ, Krishna S. Antimalarial drugs: recent advances in molecular determinants of resistance and their clinical significance. Cell Mol Life Sci. 2006;63:1386–96.
9. Arley T, Witkowski B, Armaratunga C, Beggian J, Langlois AC, Khin N, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature. 2014;505:50–5.
10. Reckmann KH, Campbell GH, Sax LJ, Mrema JE. Drug sensitivity of Plasmodium falciparum. An in-vitro microtechnique. Lancet. 1978;1:223–3.
11. Duraisingham MT, Jones P, Sambou I, Von Seelien I, Pinder M, Warhurst DC. Incolum effect leads to overestimation of in vitro resistance for artemisinin derivatives and standard antimalarials: a Gambian field study. Parasitology. 1999;119:435–40.
12. Basco LK, Marquet F, Makker MM, Le Bras J. Plasmodium falciparum and Plasmodium vivax: lactate dehydrogenase activity and its application for in vitro drug susceptibility assay. Exp Parasitol. 1995;82:266–71.
13. Noedl H, Attlmayr B, Wernsdorfer WH, Kollaritsch H, Miller RS. A histidine-rich protein 2-based malaria drug sensitivity assay for field use. Am J Trop Med Hyg. 2004;71:711–4.
14. Bacon DJ, Latour C, Lucas C, Colina O, Ringwald P, Picot S. Comparison of a SYBR green I-based assay with a histidine-rich protein II enzyme-linked immunosorbent assay for in vitro antimalarial drug efficacy testing and application to clinical isolates. Antimicrob Agents Chemother. 2007;51:1172–8.
15. Russell B, Mallaret B, Suwanarusk R, Anthony C, Kanlaya S, Lau YL, et al. Field-based flow cytometry for ex vivo characterization of Plasmodium vivax and P. falciparum antimalarial sensitivity. Antimicrob Agents Chemother. 2013;57:5170–4.
16. Noedl H, Wongsrichanalai C, Wermseforder WH. Malaria drug-sensitivity testing: new assays, new perspectives. Trends Parasitol. 2003;19:75–81.
17. Wein S, Maynadier M, Tran Van Ba C, Cerdan R, Peyrottes S, Fraise L, et al. Reliability of antimalarial sensitivity tests depends on drug mechanisms of action. J Clin Microbiol. 2010;48:1651–60.
18. Grimbett BT, Erickson JJ, Smaksimski RM, Jacobberger JW, Zimmerman PA. Monitoring Plasmodium falciparum growth and development by UV flow cytometry using an optimized Hoechst-thiazole orange staining strategy. Cytometry A. 2008;73:546–54.
19. Rebelo M, Sousa C, Shapiro HM, Mota MM, Grobusch MP, Hänscheid T. A novel flow cytometric hemotoxin detection assay for real-time sensitivity testing of Plasmodium falciparum. PLoS One. 2013;8:e61606.
20. Planche T, Krishna S, Kombila M, Engel K, Faucher JF, Ngos-Milama E, et al. Comparison of methods for the rapid laboratory assessment of children with malaria. Am J Trop Med Hyg. 2001;65:599–602.
21. Noedl H, Bronnert J, Yingsuyen K, Attlmayr B, Kollaritsch H, Fukuda M. Simple histidine-rich protein 2 double-site sandwich enzyme-linked immunosorbent assay for use in malaria drug sensitivity testing. Antimicrob Agents Chemother. 2005;49:3575–7.
22. Basco LK, Ringwald P. In vitro activities of piperaquine and other 4-aminoquinolines against clinical isolates of Plasmodium falciparum in Cameroon. Antimicrob Agents Chemother. 2005;49:546–54.
23. Gritzmacher CA, Reese RT. Protein and nucleic acid synthesis during synchronized growth of Plasmodium falciparum. J Bacteriol. 1984;160:1165–7.
24. Lopez Antunano FJ, Wermseforder WH. In vitro response of chloroquine resistant Plasmodium falciparum to mefloquine. Bull World Health Organ. 1979;57:665–5.
25. Ibata H, Ohmoe H, Kano S, Faarado L, Boaz L, Leafao L, et al. Variation of incubation time in an in vitro drug susceptibility test of Plasmodium falciparum isolates studied in the Solomon Islands. Parasitol Int. 2001;50:9–13.
26. Nielsen MA, Stadeo T. Establishment of long-term in vitro cultures of Plasmodium falciparum from patient blood. In: Moll K, Ljungstrom J, Perfmann H, Schef A, Wahlgren M, editors. Methods in Malaria Research. 5th ed. Manassas, Virginia: MNWATCC; 2006. p. 4–6.
27. Lim P, Chirn P, Sem R, Nemh S, Poravuth Y, Lim C, et al. In vitro monitoring of Plasmodium falciparum susceptibility to artesunate, mefloquine, quinine and chloroquine in Cambodia: 2001–2002. Acta Trop. 2005;93:31–40.
28. Kaddouri H, Nakache S, Houzé S, Mentfé F, Le Bras J. Assessment of the drug susceptibility of Plasmodium falciparum clinical isolates from Africa by using a Plasmodium lactate dehydrogenase immunodetection assay and an inhibitory maximum effect model for precise measurement of the 50-percent inhibitory concentration. Antimicrob Agents Chemother. 2004;50:3343–9.
29. Rason MA, Randriantsoa T, Andrianantenina H, Ratsimbasona A, Menard D. Performance and reliability of the SYBR Green I based assay for the routine monitoring of susceptibility of Plasmodium falciparum clinical isolates. Trans R Soc Trop Med Hyg. 2008;102:346–51.
30. Legrand E, Volney B, Meynard JB, Mercereau-Puijalon O, Esterre P. Cytometry A. 2008;73:546–54.
31. Van Schalkwyk DA, Burrow R, Henriques G, Gadalla NB, Beshir KB, Hasford C, et al. Culture-adapted Plasmodium falciparum isolates from UK travellers: in vitro drug sensitivity, clonality and drug resistance markers. Malar J. 2013;12:320.
32. Witkowski B, Amarantunga C, Khim N, Sreng S, Chhim P, Kim S, et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia. In: vitro and ex vivo drug-response studies. Lancet Infect Dis. 2013;13:1043–9.

33. Rebello M, Shapiro HM, Amanal T, Meto-Cristino J, Hænscheid T. Haemoglobin detection in infected erythrocytes for Plasmodium falciparum malaria diagnosis—Prospects and limitations. Acta Trop. 2012;123:88–61.

34. Basco LK. Molecular epidemiology of malaria in Cameroon. XX. Experimental studies on various in vitro drug sensitivity assays using fresh isolates of Plasmodium falciparum. Am J Trop Med Hyg. 2004;70:474–80.

35. Held J, Soomro SA, Kremsner PG, Jansen FH, Mordmuller B. In vitro activity of new artemisinin derivatives against Plasmodium falciparum clinical isolates from Gabon. Int J Antimicrob Agents. 2013;37:485–8.

36. Grobusch MP, Adagu IS, Kremsner PG, Warhurst DC. Plasmodium falciparum in vitro chloroquine susceptibility and allele-specific PCR detection of Pfmdr1Asn86Tyr polymorphism in Lambaréné, Gabon. Parasitology. 1998;116:211–7.

37. Borrmann S, Binder RK, Adegnika AA, Missinou MA, Issifou S, Ramharter M, et al. Reassessment of the resistance of Plasmodium falciparum to chloroquine in Gabon: implications for the validity of tests in vitro vs. in vivo. Trans R Soc Trop Med Hyg. 2002;96:660–3.

38. Kublin JG, Contesse JF, Njenu EM, Mukadam RA, Wirima JJ, Kazembe PN, et al. Reemergence of chloroquine sensitive Plasmodium falciparum malaria after cessation of chloroquine use in Malawi. J Infect Dis. 2003;187:1870–5.

39. Laufer MK, Thesing PC, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, et al. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med. 2006;355:1959–66.

40. Mwai L, Ochong E, Abdrahman A, Kiara SM, Ward S, Kokwaro G, et al. Chloroquine resistance before and after its withdrawal in Kenya. Malar J. 2009;8:106.

41. Allfang M, Lusingu JP, Mbanda B, Dalgaard MB, Westergaard LS, Ishengoma D, et al. Five-year surveillance of molecular markers of Plasmodium falciparum antimalarial drug resistance in Korogwe District, Tanzania: accumulation of the S86T mutation in the P. falciparum dihydropteroate synthase gene. Am J Trop Med Hyg. 2009;80:523–7.

42. Frank M, Lehners N, Mayengue P, Gabor J, Dal-Bianco M, Kombila DU, et al. A thirteen-year analysis of Plasmodium falciparum populations reveals high conservation of the mutant pfcrt haplotype despite the withdrawal of chloroquine from national treatment guidelines in Gabon. Malar J. 2011;10:304.

43. Djimdet AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, et al. Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am J Trop Med Hyg. 2008;78:455–61.

44. Gorka AP, De Dios A, Roepe PD. Quinoline drug-heme interactions and implications for antimalarial cytostatic versus cytocidal activities. J Med Chem. 2013;56:3231–46.

45. Rebello M, Tempera C, Eddington ND, Masonga R, Dzinjalamala FK, Takala SL, et al. Return of chloroquine antimalarial efficacy in Malawi. N Engl J Med. 2006;355:1959–66.

46. Noedl H, Krudsood S, Leowattana W, Tangpakdee N, Thanhchartwat W, Loaereeuanun S, et al. In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome: Antimicrob Agents Chemother. 2007;51:651–6.

47. Amarantunga C, Neal AT, Fairhurst RM. Flow cytometry-based analysis of artemisinin-resistant Plasmodium falciparum in the ring-stage survival assay. Antimicrob Agents Chemother. 2014;58:4938–40.

48. Partec. CytFlow Cube 6. http://www.sysmex-partec.com/fileadmin/media/pdf/CyFlow-Cube6.pdf. Accessed: 17 December 2014.

49. Boyle DS, Hawkins KR, Steele MS, Singleton M, Cheng X. Emerging technologies for point-of-care CD4 T-lymphocyte counting. Trends Biotechnol. 2012;30:45–54.

50. Shapiro HM, Mandy F. Cytometry in malaria: moving beyond Giemsa. Cytometry A. 2007;71:643–5.

51. Shapiro HM, Apte SH, Chojnowski GM, Hænscheid T, Rebello M, Grimberg BT. Cytometry in malaria—a practical replacement for microscopy? Curr Protoc Cytom. 2013;11:1–20.

52. Maguire JD, Lederman ER, Barcus MJ, O’Meara WA, Jordon RG, Duong S, et al. Production and validation of durable, high quality standardized malaria microscopy slides for teaching, testing and quality assurance during an era of declining diagnostic proficiency. Malar J. 2006;5:92.